# ErVaccine Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ervaccine-technologies

- Industry: Biotechnology
- Headquarters: Lyon, France
- Website: www.ervaccinetechnologies.com
- Total disclosed funding: $1.4M
- Latest round: Seed (Feb 5, 2021)
- Investors on record: 1

## About

Based in Lyon, France, ErVaccine Technologies operates as a developer of immunotherapeutic approaches targeting human endogenous retroviruses. The company was founded by CEO Stephane Depil, MD, Ph.D.

The company's platform uses HERVS which are ancestrally-acquired viral elements that persist in the human microbiome (virome) and are activated in many cancer types that enable its patients to have access to cancer vaccines.

The company generates revenue by offering the developed therapies to pharmaceutical companies.

As of February 2021, The company raised EUR 2.5 million from seed funding led by Seventure. The fund will be used for further development of pre-clinical trials.

## Funding rounds

- Seed, Feb 5, 2021, $1.4M — Seventure Partners

## Investors

- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Seed